<DOC>
	<DOCNO>NCT00329719</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose temsirolimus give together sorafenib see well work treat patient recurrent glioblastoma . Sorafenib may stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , temsirolimus , work different way stop growth tumor cell , either kill cell stop dividing . Sorafenib temsirolimus may also stop growth tumor cell block enzymes need cell growth . Giving sorafenib together temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib Temsirolimus Treating Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>Primary Objective - Phase I ( close accrual 01/11/2008 ) : To establish maximum tolerable dose temsirolimus combination sorafenib patient recurrent glioblastoma receive enzyme-inducing anticonvulsant ( EIACs ) . Phase II ( close accrual 12/07/2012 ) : To assess efficacy temsirolimus sorafenib treatment recurrent glioblastoma non-EIAC patient measure progression-free survival status six month ( PFS6 ) . Secondary Objectives - Phase I ( close accrual 01/11/2008 ) : I . To define safety profile temsirolimus sorafenib non-EIAC patient . II . To assess evidence antitumor activity . Phase II ( close accrual 12/07/2012 ) : I . To assess safety toxicity temsirolimus sorafenib above-noted patient population . Outline : This multicenter , phase I , dose-escalation study follow phase II study . Phase I ( Arm A ) : Patients receive sorafenib orally ( PO ) twice daily ( BID ) day 1-28 temsirolimus intravenously ( IV ) 30 minute day 1 , 8 , 15 , 22 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos temsirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Phase II : Patients assign 1 3 treatment group . Group 1 ( Arm B ) : Patients receive sorafenib temsirolimus phase I MTD . ( patient undergo surgery ) Group 2 ( Arm C ) : Patients receive sorafenib PO BID day 1-8 ( 15 dos ) temsirolimus IV MTD day 1 . Patients undergo surgery day 8 . ( patient undergo surgery ) After recover surgery , patient receive sorafenib temsirolimus phase I MTD . Group 3 ( Arm D ) : Patient receive sorafenib temsirolimus phase I MTD . ( patient receive prior anti-vascular endothelial growth factor [ VEGF ] therapy undergo surgery ) Biopsy resect tissue blood collect prior treatment ( usually diagnosis ) analyze biomarkers . After completion study treatment , patient follow every 6 month 5 year annually thereafter .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Central pathology review submission prior registration confirm eligibility . It initiate soon surgery possible . ≤2 prior systemic chemotherapy regimen . ≥18 year age . Histological confirmation grade 4 astrocytoma ( glioblastoma ) gliosarcoma , primary diagnosis recurrence World Health Organization ( WHO ) criterion . Central pathology review mandatory prior study entry confirm eligibility . Evidence tumor progression Magnetic Resonance Imaging ( MRI ) Computerized Tomography ( CT ) scan follow Radiation Therapy ( RT ) follow recent antitumor therapy . Bidimensionally measurable evaluable disease MRI CT scan . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 , 1 , 2 . ≥12 week since completion RT . Fixed decrease dose corticosteroid ( corticosteroid ) ≥1 week prior registration . ≥1 week minor surgery venous line placement &gt; 3 week major surgery . ≥4 week prior cytotoxic chemotherapy ( ≥6 week nitrosoureas ) . ≥2 week cytostatic chemotherapy tamoxifen , cisretinoic acid , thalidomide . The following laboratory value obtain ≤7 day prior registration : WBC ≥3000/mm3 ANC ≥1500/mm3 PLT ≥100,000/mm3 Hgb ≥10 gm/dL Total bilirubin ≤1.5 x ULN SGOT ( AST ) ≤2.5 x ULN Creatinine ≤2.0 x ULN Serum cholesterol ≤350 mg/dL Serum triglycerides ≤400 mg/dL Willingness provide biologic specimen require protocol . ( Please note willingness participate pertains patient factor institution 's ability participate part translational component . ) Prior intratumoral chemotherapy ( e.g . Gliadel IL13PE38QQR ) , stereotactic radiosurgery interstitial brachytherapy unless separate lesion MRI part previous treatment field proof recurrent disease base biopsy , MRI spectroscopy , Positron Emission Tomography ( PET ) scan . Prior CCI779 , sorafenib , agent specifically target mTOR raf . Patients receive prior agent inhibit VEGF VEGFR ( prior antiVEGF group ) eligible : 1 ) must least four week last treatment agent ( ) ; 2 ) must recover clinically relevant toxicity attributable agent ( ) . Evidence bleed diathesis coagulopathy . Note : Patients prophylactic anticoagulation therapy ( e.g. , lowdose warfarin ) eligible provide coagulation parameter level follow : prothrombin time ( INR ; International Normalized Ratio prothrombin time ) &lt; 1.1 x institutional upper limit normal . Note : Patients fulldose anticoagulant ( e.g. , warfarin ) eligible provide follow criterion meet : ) patient inrange INR ( usually 2 3 ) stable dose oral anticoagulant stable dose low molecular weight heparin , b ) patient active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) . INR &gt; 1.5 ( unless patient full dose warfarin ) . Receiving enzymeinducing antiepileptic drug ( EIAEDs ; e.g. , phenytoin , fosphenytoin , carbamazepine , phenobarbital , primidone ) potent CYP3A4 inducer rifampin St. John 's wort . Any condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) impair ability swallow pill . Hypertension systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg . However , patient wellcontrolled hypertension eligible . Uncontrolled infection . Any following temsirolimus sorafenib investigational agent whose genotoxic effect develop fetus newborn unknown : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Known hypersensitivity component temsirolimus sorafenib . Other active malignancy . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Immunocompromised patient ( relate use corticosteroid ) include patient know HIV positive . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction temsirolimus sorafenib . Receiving investigational agent temsirolimus sorafenib . Significant intratumoral , intracerebral , subarachnoid hemorrhage baseline MRI CT , history significant intratumoral , intracerebral , subarachnoid hemorrhage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>